 | • レポートコード：MRC2-11QY05054 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はフォンウィルブランド病（VWD）治療薬のグローバル市場について調査・分析したレポートです。種類別（デスモプレシン、血栓安定化薬、線維素溶解阻害剤、補充療法、その他）市場規模、用途別（病院薬局、小売薬局、オンライン薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別フォンウィルブランド病（VWD）治療薬の競争状況、市場シェア ・世界のフォンウィルブランド病（VWD）治療薬市場：種類別市場規模 2015年-2020年（デスモプレシン、血栓安定化薬、線維素溶解阻害剤、補充療法、その他） ・世界のフォンウィルブランド病（VWD）治療薬市場：種類別市場規模予測 2021年-2026年（デスモプレシン、血栓安定化薬、線維素溶解阻害剤、補充療法、その他） ・世界のフォンウィルブランド病（VWD）治療薬市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局、オンライン薬局） ・世界のフォンウィルブランド病（VWD）治療薬市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局、オンライン薬局） ・北米のフォンウィルブランド病（VWD）治療薬市場分析：米国、カナダ ・ヨーロッパのフォンウィルブランド病（VWD）治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのフォンウィルブランド病（VWD）治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のフォンウィルブランド病（VWD）治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのフォンウィルブランド病（VWD）治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Apollo Therapeutics、Apotex、Bayer、Bio Products Laboratory、CSL、Ferring Pharmaceuticals、Glenmark Pharmaceuticals、Grifols、Octapharma、Takeda ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Von Willebrand Disease is an inherited bleeding disorder that is caused by deficiency or dysfunction of Von Willebrand Factor (VWF). VWF is a plasma protein that mediates the initial adhesion of platelets at sites of vascular injury. This protein also binds to clotting factor VIII (FVIII) in the circulation and stabilizes it.
Symptoms of Von Willebrand Disease include prolonged bleeding from skin lacerations, bleeding from nose and gums, and menorrhagia.
Different types of therapeutics have been utilized in the treatment of von Willebrand Disease, including desmopressin, clot-stabilizing medications, replacement therapies, contraceptives, and others. Desmopressin is extensively used in the treatment of von Willebrand disease.
Market Analysis and Insights: Global Von Willebrand Disease (VWD) Therapeutics Market
The global Von Willebrand Disease (VWD) Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Von Willebrand Disease (VWD) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Von Willebrand Disease (VWD) Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Von Willebrand Disease (VWD) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Von Willebrand Disease (VWD) Therapeutics market.
Global Von Willebrand Disease (VWD) Therapeutics Scope and Segment
Von Willebrand Disease (VWD) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Von Willebrand Disease (VWD) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Distribution Channel in terms of revenue and forecast for the period 2015-2026.
Market segment by Type, the product can be split into
Desmopressin
Clot-Stabilizing Medication
Fibrinolytic Inhibitors
Replacement Therapy
Others
Market segment by Distribution Channel, split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Based on regional and country-level analysis, the Von Willebrand Disease (VWD) Therapeutics market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
In the competitive analysis section of the report, leading as well as prominent players of the global Von Willebrand Disease (VWD) Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
Apollo Therapeutics
Apotex
Bayer
Bio Products Laboratory
CSL
Ferring Pharmaceuticals
Glenmark Pharmaceuticals
Grifols
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Market Analysis by Type
1.3.1 Global Von Willebrand Disease (VWD) Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.3.2 Desmopressin
1.3.3 Clot-Stabilizing Medication
1.3.4 Fibrinolytic Inhibitors
1.3.5 Replacement Therapy
1.3.6 Others
1.4 Market by Application
1.4.1 Global Von Willebrand Disease (VWD) Therapeutics Market Share by Distribution Channel: 2020 VS 2026
1.4.2 Hospital Pharmacies
1.4.3 Retail Pharmacies
1.4.4 Online Pharmacies
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Von Willebrand Disease (VWD) Therapeutics Market Perspective (2015-2026)
2.2 Von Willebrand Disease (VWD) Therapeutics Growth Trends by Regions
2.2.1 Von Willebrand Disease (VWD) Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Von Willebrand Disease (VWD) Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Von Willebrand Disease (VWD) Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Von Willebrand Disease (VWD) Therapeutics Industry Dynamic
2.3.1 Von Willebrand Disease (VWD) Therapeutics Market Trends
2.3.2 Von Willebrand Disease (VWD) Therapeutics Market Drivers
2.3.3 Von Willebrand Disease (VWD) Therapeutics Market Challenges
2.3.4 Von Willebrand Disease (VWD) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Von Willebrand Disease (VWD) Therapeutics Players by Market Size
3.1.1 Global Top Von Willebrand Disease (VWD) Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Von Willebrand Disease (VWD) Therapeutics Revenue Market Share by Players (2015-2020)
3.2 Global Von Willebrand Disease (VWD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Von Willebrand Disease (VWD) Therapeutics Revenue
3.4 Global Von Willebrand Disease (VWD) Therapeutics Market Concentration Ratio
3.4.1 Global Von Willebrand Disease (VWD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Von Willebrand Disease (VWD) Therapeutics Revenue in 2019
3.5 Key Players Von Willebrand Disease (VWD) Therapeutics Area Served
3.6 Key Players Von Willebrand Disease (VWD) Therapeutics Product Solution and Service
3.7 Date of Enter into Von Willebrand Disease (VWD) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Von Willebrand Disease (VWD) Therapeutics Breakdown Data by Type
4.1 Global Von Willebrand Disease (VWD) Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Von Willebrand Disease (VWD) Therapeutics Forecasted Market Size by Type (2021-2026)
5 Von Willebrand Disease (VWD) Therapeutics Breakdown Data by Distribution Channel
5.1 Global Von Willebrand Disease (VWD) Therapeutics Historic Market Size by Distribution Channel (2015-2020)
5.2 Global Von Willebrand Disease (VWD) Therapeutics Forecasted Market Size by Distribution Channel (2021-2026)
6 North America
6.1 North America Von Willebrand Disease (VWD) Therapeutics Market Size (2015-2026)
6.2 North America Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2015-2020)
6.3 North America Von Willebrand Disease (VWD) Therapeutics Market Size by Distribution Channel (2015-2020)
6.4 North America Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Von Willebrand Disease (VWD) Therapeutics Market Size (2015-2026)
7.2 Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2015-2020)
7.3 Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Distribution Channel (2015-2020)
7.4 Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size (2015-2026)
8.2 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2015-2020)
8.3 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Distribution Channel (2015-2020)
8.4 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
9 Latin America
9.1 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size (2015-2026)
9.2 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2015-2020)
9.3 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Distribution Channel (2015-2020)
9.4 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size (2015-2026)
10.2 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2015-2020)
10.3 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2015-2020)
10.4 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11Key Players Profiles
11.1 Apollo Therapeutics
11.1.1 Apollo Therapeutics Company Details
11.1.2 Apollo Therapeutics Business Overview
11.1.3 Apollo Therapeutics Von Willebrand Disease (VWD) Therapeutics Introduction
11.1.4 Apollo Therapeutics Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020))
11.1.5 Apollo Therapeutics Recent Development
11.2 Apotex
11.2.1 Apotex Company Details
11.2.2 Apotex Business Overview
11.2.3 Apotex Von Willebrand Disease (VWD) Therapeutics Introduction
11.2.4 Apotex Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.2.5 Apotex Recent Development
11.3 Bayer
11.3.1 Bayer Company Details
11.3.2 Bayer Business Overview
11.3.3 Bayer Von Willebrand Disease (VWD) Therapeutics Introduction
11.3.4 Bayer Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.3.5 Bayer Recent Development
11.4 Bio Products Laboratory
11.4.1 Bio Products Laboratory Company Details
11.4.2 Bio Products Laboratory Business Overview
11.4.3 Bio Products Laboratory Von Willebrand Disease (VWD) Therapeutics Introduction
11.4.4 Bio Products Laboratory Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.4.5 Bio Products Laboratory Recent Development
11.5 CSL
11.5.1 CSL Company Details
11.5.2 CSL Business Overview
11.5.3 CSL Von Willebrand Disease (VWD) Therapeutics Introduction
11.5.4 CSL Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.5.5 CSL Recent Development
11.6 Ferring Pharmaceuticals
11.6.1 Ferring Pharmaceuticals Company Details
11.6.2 Ferring Pharmaceuticals Business Overview
11.6.3 Ferring Pharmaceuticals Von Willebrand Disease (VWD) Therapeutics Introduction
11.6.4 Ferring Pharmaceuticals Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.6.5 Ferring Pharmaceuticals Recent Development
11.7 Glenmark Pharmaceuticals
11.7.1 Glenmark Pharmaceuticals Company Details
11.7.2 Glenmark Pharmaceuticals Business Overview
11.7.3 Glenmark Pharmaceuticals Von Willebrand Disease (VWD) Therapeutics Introduction
11.7.4 Glenmark Pharmaceuticals Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.7.5 Glenmark Pharmaceuticals Recent Development
11.8 Grifols
11.8.1 Grifols Company Details
11.8.2 Grifols Business Overview
11.8.3 Grifols Von Willebrand Disease (VWD) Therapeutics Introduction
11.8.4 Grifols Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.8.5 Grifols Recent Development
11.9 Octapharma
11.9.1 Octapharma Company Details
11.9.2 Octapharma Business Overview
11.9.3 Octapharma Von Willebrand Disease (VWD) Therapeutics Introduction
11.9.4 Octapharma Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.9.5 Octapharma Recent Development
11.10 Takeda
11.10.1 Takeda Company Details
11.10.2 Takeda Business Overview
11.10.3 Takeda Von Willebrand Disease (VWD) Therapeutics Introduction
11.10.4 Takeda Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
11.10.5 Takeda Recent Development
12Analyst’s Viewpoints/Conclusions
13Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Von Willebrand Disease (VWD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 2. Key Players of Desmopressin
Table 3. Key Players of Clot-Stabilizing Medication
Table 4. Key Players of Fibrinolytic Inhibitors
Table 5. Key Players of Replacement Therapy
Table 6. Key Players of Others
Table 7. Global Von Willebrand Disease (VWD) Therapeutics Market Size Growth by Distribution Channel (US$ Million): 2020 VS 2026
Table 8. Global Von Willebrand Disease (VWD) Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Von Willebrand Disease (VWD) Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Von Willebrand Disease (VWD) Therapeutics Market Share by Regions (2015-2020)
Table 11. Global Von Willebrand Disease (VWD) Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Von Willebrand Disease (VWD) Therapeutics Market Share by Regions (2021-2026)
Table 13. Von Willebrand Disease (VWD) Therapeutics Market Market Trends
Table 14. Von Willebrand Disease (VWD) Therapeutics Market Drivers
Table 15. Von Willebrand Disease (VWD) Therapeutics Market Challenges
Table 16. Von Willebrand Disease (VWD) Therapeutics Market Restraints
Table 17. Global Von Willebrand Disease (VWD) Therapeutics Revenue by Players (2015-2020) (US$ Million)
Table 18. Global Von Willebrand Disease (VWD) Therapeutics Market Share by Players (2015-2020)
Table 19. Global Top Von Willebrand Disease (VWD) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Von Willebrand Disease (VWD) Therapeutics as of 2019)
Table 20. Global Von Willebrand Disease (VWD) Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Von Willebrand Disease (VWD) Therapeutics Product Solution and Service
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 25. Global Von Willebrand Disease (VWD) Therapeutics Revenue Market Share by Type (2015-2020)
Table 26. Global Von Willebrand Disease (VWD) Therapeutics Forecasted Market Size by Type (2021-2026) (US$ Million)
Table 27. Global Von Willebrand Disease (VWD) Therapeutics Market Size Share by Distribution Channel (2015-2020) (US$ Million)
Table 28. Global Von Willebrand Disease (VWD) Therapeutics Revenue Market Share by Distribution Channel (2015-2020)
Table 29. Global Von Willebrand Disease (VWD) Therapeutics Forecasted Market Size by Distribution Channel (2021-2026) (US$ Million)
Table 30. North America Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 31. North America Von Willebrand Disease (VWD) Therapeutics Market Share by Type (2015-2020)
Table 32. North America Von Willebrand Disease (VWD) Therapeutics Market Size by Distribution Channel (2015-2020) (US$ Million)
Table 33. North America Von Willebrand Disease (VWD) Therapeutics Market Share by Distribution Channel (2015-2020)
Table 34. North America Von Willebrand Disease (VWD) Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 35. North America Von Willebrand Disease (VWD) Therapeutics Market Share by Country (2015-2020)
Table 36. Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 37. Europe Von Willebrand Disease (VWD) Therapeutics Market Share by Type (2015-2020)
Table 38. Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Distribution Channel (2015-2020) (US$ Million)
Table 39. Europe Von Willebrand Disease (VWD) Therapeutics Market Share by Distribution Channel (2015-2020)
Table 40. Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 41. Europe Von Willebrand Disease (VWD) Therapeutics Market Share by Country (2015-2020)
Table 42. Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 43. Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Share by Type (2015-2020)
Table 44. Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Distribution Channel (2015-2020) (US$ Million)
Table 45. Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Share by Distribution Channel (2015-2020)
Table 46. Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Region (US$ Million) (2015-2020)
Table 47. Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Share by Region (2015-2020)
Table 48. Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 49. Latin America Von Willebrand Disease (VWD) Therapeutics Market Share by Type (2015-2020)
Table 50. Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Distribution Channel (2015-2020) (US$ Million)
Table 51. Latin America Von Willebrand Disease (VWD) Therapeutics Market Share by Distribution Channel (2015-2020)
Table 52. Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 53. Latin America Von Willebrand Disease (VWD) Therapeutics Market Share by Country (2015-2020)
Table 54. Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 55. Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Share by Type (2015-2020)
Table 56. Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Distribution Channel (2015-2020) (US$ Million)
Table 57. Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Share by Distribution Channel (2015-2020)
Table 58. Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 59. Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Share by Country (2015-2020)
Table 60. Apollo Therapeutics Company Details
Table 61. Apollo Therapeutics Business Overview
Table 62. Apollo Therapeutics Von Willebrand Disease (VWD) Therapeutics Product
Table 63. Apollo Therapeutics Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020) (US$ Million)
Table 64. Apollo Therapeutics Recent Development
Table 65. Apotex Company Details
Table 66. Apotex Business Overview
Table 67. Apotex Von Willebrand Disease (VWD) Therapeutics Product
Table 68. Apotex Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020) (US$ Million)
Table 69. Apotex Recent Development
Table 70. Bayer Company Details
Table 71. Bayer Business Overview
Table 72. Bayer Von Willebrand Disease (VWD) Therapeutics Product
Table 73. Bayer Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020) (US$ Million)
Table 74. Bayer Recent Development
Table 75. Bio Products Laboratory Company Details
Table 76. Bio Products Laboratory Business Overview
Table 77. Bio Products Laboratory Von Willebrand Disease (VWD) Therapeutics Product
Table 78. Bio Products Laboratory Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020) (US$ Million)
Table 79. Bio Products Laboratory Recent Development
Table 80. CSL Company Details
Table 81. CSL Business Overview
Table 82. CSL Von Willebrand Disease (VWD) Therapeutics Product
Table 83. CSL Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020) (US$ Million)
Table 84. CSL Recent Development
Table 85. Ferring Pharmaceuticals Company Details
Table 86. Ferring Pharmaceuticals Business Overview
Table 87. Ferring Pharmaceuticals Von Willebrand Disease (VWD) Therapeutics Product
Table 88. Ferring Pharmaceuticals Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020) (US$ Million)
Table 89. Ferring Pharmaceuticals Recent Development
Table 90. Glenmark Pharmaceuticals Company Details
Table 91. Glenmark Pharmaceuticals Business Overview
Table 92. Glenmark Pharmaceuticals Von Willebrand Disease (VWD) Therapeutics Product
Table 93. Glenmark Pharmaceuticals Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020) (US$ Million)
Table 94. Glenmark Pharmaceuticals Recent Development
Table 95. Grifols Business Overview
Table 96. Grifols Von Willebrand Disease (VWD) Therapeutics Product
Table 97. Grifols Company Details
Table 98. Grifols Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020) (US$ Million)
Table 99. Grifols Recent Development
Table 100. Octapharma Company Details
Table 101. Octapharma Business Overview
Table 102. Octapharma Von Willebrand Disease (VWD) Therapeutics Product
Table 103. Octapharma Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020) (US$ Million)
Table 104. Octapharma Recent Development
Table 105. Takeda Company Details
Table 106. Takeda Business Overview
Table 107. Takeda Von Willebrand Disease (VWD) Therapeutics Product
Table 108. Takeda Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020) (US$ Million)
Table 109. Takeda Recent Development
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Von Willebrand Disease (VWD) Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Desmopressin Features
Figure 3. Clot-Stabilizing Medication Features
Figure 4. Fibrinolytic Inhibitors Features
Figure 5. Replacement Therapy Features
Figure 6. Others Features
Figure 7. Global Von Willebrand Disease (VWD) Therapeutics Market Share by Distribution Channel: 2020 VS 2026
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Online Pharmacies Case Studies
Figure 11. Von Willebrand Disease (VWD) Therapeutics Report Years Considered
Figure 12. Global Von Willebrand Disease (VWD) Therapeutics Market Size (US$ Million), YoY Growth 2015-2026
Figure 13. Global Von Willebrand Disease (VWD) Therapeutics Market Share by Regions: 2020 VS 2026
Figure 14. Global Von Willebrand Disease (VWD) Therapeutics Market Share by Regions (2021-2026)
Figure 15. Global Von Willebrand Disease (VWD) Therapeutics Market Share by Players in 2019
Figure 16. Global Top Von Willebrand Disease (VWD) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Von Willebrand Disease (VWD) Therapeutics as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Von Willebrand Disease (VWD) Therapeutics Revenue in 2019
Figure 18. North America Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 19. United States Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 20. Canada Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 21. Europe Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 22. Germany Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 23. France Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 24. U.K. Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 25. Italy Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 26. Russia Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 27. Nordic Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 28. Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 29. China Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 30. Japan Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 31. South Korea Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 32. Southeast Asia Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 33. India Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 34. Australia Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 35. Rest of Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 36. Latin America Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 37. Mexico Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 38. Brazil Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 39. Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 40. Turkey Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 41. Saudi Arabia Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 42. UAE Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 43. Apollo Therapeutics Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
Figure 44. Apotex Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
Figure 45. Bayer Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
Figure 46. Bio Products Laboratory Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
Figure 47. CSL Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
Figure 48. Ferring Pharmaceuticals Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
Figure 49. Glenmark Pharmaceuticals Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
Figure 50. Grifols Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
Figure 51. Octapharma Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
Figure 52. Takeda Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2015-2020)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
胃食道逆流症（GERD）治療薬の世界市場（～2026年） Gastroesophageal reflux disease (GERD), also known as acid reflux, is a long-term condition where stomach contents come back up into the esophagus resulting in either symptoms or complications. Patent expiry of blockbuster drugs prescribed for the treatment of acid reflux disorders is majorly attrib…- クッシング病治療の世界市場（～2026年） Cushing disease is caused by tumour in the pituitary gland which leads to excessive secretion of a hormone called adrenocorticotrophic (ACTH), which in turn leads to increasing levels of cortisol in the body. Cortisol is a steroid hormone released by the adrenal glands and helps the body to deal wit…
- 獣医感染症治療薬の世界市場（～2026年） Market Analysis and Insights: Global Veterinary Infectious Disease Therapeutics Market The global Veterinary Infectious Disease Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Veterinary Infectious Disease…
- 希少内分泌疾患治療の世界市場（～2026年） The endocrine system is a chemical messenger system consisting of hormones, the group of glands of an organism that carry those hormones directly into the circulatory system to be carried towards distant target organs and the feedback loops of homeostasis that the hormones drive. The rare endocrine …
- アルツハイマー病治療薬の世界市場（～2026年） Alzheimer’s disease is a neurodegenerative, progressive, non-reversible disorder. Alzheimer’s disease is caused due to abnormal functioning of brain cells i.e. failure of synaptic transmission, resulting in the loss of cognitive functions. Some of the signs and symptoms of alzheimer’s disease are me…